Earnings Call Summary | Harrow(HROW.US) Q1 2024 Earnings Conference
Earnings Call Summary | Harrow(HROW.US) Q1 2024 Earnings Conference
The following is a summary of the Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript:
以下是哈羅公司（HROW）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Harrow Inc. reported a rise of 33% in revenues for Q1 2024 compared to Q1 2023.
Increased its covered lives from 40+ million to 150+ million within two months.
Core gross margins, after excluding non-cash expense of acquisition NDAs, are projected to rise from mid-70s to low-80s by the end of 2024.
The company holds $76 million in cash and cash equivalents.
Managing EBITDA to stay under a leverage ratio of five times, and plan to gradually increase sales, marketing, and G&A expenditure.
哈羅公司報告稱，與2023年第一季度相比，2024年第一季度的收入增長了33％。
在兩個月內，其承保壽命從4000多萬增加到1.5億。
扣除收購保密協議的非現金支出後，預計到2024年底，核心毛利率將從70年代中期升至80年代的低點。
該公司持有7600萬美元的現金和現金等價物。
管理息稅折舊攤銷前利潤，將槓桿率保持在五倍以下，並計劃逐步增加銷售、營銷和併購支出。
Business Progress:
業務進展：
Added Greg DiPasquale to its management team focusing on sales, marketing, and sales operations activities for branded ophthalmic products.
Launched two products, VEVYE and IHEEZO, which have been positively received in the market.
PPQ batch of TRIESENCE manufactured and passed preliminary release parameters.
Progressing with Anterior Segment products expecting good returns.
Continues to sign agreements with large multi-practice organizations to improve order draw from various accounts.
Aims to become a leading player in the North American ophthalmic pharmaceuticals industry, as per their five-year strategic plan.
Greg DipaSquale加入其管理團隊，主要負責品牌眼科產品的銷售、營銷和銷售運營活動。
推出了兩款產品，VEVYE和IHEEZO，在市場上受到了好評。
PPQ 批次 TRIESENCE 製造並通過了初步的發佈參數。
前段產品的開發正在取得進展，預計會有良好的回報。
繼續與大型多業務組織簽署協議，以改善來自不同賬戶的訂單。
根據其五年戰略計劃，目標是成爲北美眼科製藥行業的領先者。
More details: Harrow IR
更多詳情： 哈羅紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。